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Substantial epidemiological studies suggest that not only, being one of the reasons for
the transmission of the human immunodeficiency virus (HIV), but drug abuse also serves
its role in determining the disease progression and severity among the HIV infected
population. This article focuses on the drug cocaine, and its role in facilitating entry
of HIV into the CNS and mechanisms of development of neurologic complications in
infected individuals. Cocaine is a powerfully addictive central nervous system stimulating
drug, which increases the level of neurotransmitter dopamine (DA) in the brain, by
blocking the dopamine transporters (DAT) which is critical for DA homeostasis and
neurocognitive function. Tat protein of HIV acts as an allosteric modulator of DAT, where
as cocaine acts as reuptake inhibitor. When macrophages in the CNS are exposed to
DA, their number increases. These macrophages release inflammatory mediators and
neurotoxins, causing chronic neuroinflammation. Cocaine abuse during HIV infection
enhances the production of platelet monocyte complexes (PMCs), which may cross
transendothelial barrier, and result in HIV-associated neurocognitive disorder (HAND).
HAND is characterized by neuroinflammation, including astrogliosis, multinucleated giant
cells, and neuronal apoptosis that is linked to progressive virus infection and immune
deterioration. Cocaine and viral proteins are capable of eliciting signaling transduction
pathways in neurons, involving inmitochondrial membrane potential loss, oxidative stress,
activation of JNK, p38, and ERK/MAPK pathways, and results in downstream activation
of NF-kB that leads to HAND. Tat-induced inflammation provokes permeability of the
blood brain barrier (BBB) in the platelet dependent manner, which can potentially be
the reason for progression to HAND during HIV infection. A better understanding on the
role of cocaine in HIV infection can give a clue in developing novel therapeutic strategies
against HIV-1 infection in cocaine using HIV infected population.
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Introduction
Acquired immunodeficiency syndrome (AIDS) is a condition caused by a virus called human
immunodeficiency virus (HIV). AIDS is one of the most critically acclaimed endemic diseases,
caused by lentivirus HIV-1 and HIV-2 which fatally impairs the immune system (Diwan et al.,
2013). According to the 2013 World Health Organization report over 35 million people were living
Frontiers in Microbiology | www.frontiersin.org September 2015 | Volume 6 | Article 9311
Dahal et al. Cocaine drug abuse and HIV
FIGURE 1 | Prevalence of cocaine use in 2010 (UNODC). Source: UNODC estimates based on annual report questionnaire data and other official sources. The
bound-aries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations. Final boundary
between the Republic of Sudan and the Republic of South Sudan has not yet been determined. Dashed lines represent undermined bound-aries. Dotted line
represents approximately the line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been
agreed upon by the parties. The final boundary between the Republic of Sudan and the Republic of South Sudan has not yet been determined.
with HIV. HIV infection and progression of AIDS can be
modulated by a number of cofactors, including drugs of
abuse such as opioids, cocaine, cannabinoids, methamphetamine,
alcohol, and others. According to the United Nations Office
on Drugs and Crime (UNODC) (2012), about 230 million
people (15–64 age group, Figure 1) are estimated to have
used an illicit drug and estimated number of problem drug
users in 2010 was between 15.5 million and 38.6 million
and more over drug users continue to be a problem with
drug dependence disorders such as the prevalence of HIV
(20%), hepatitis C (46.7%) and hepatitis B (14.6%). Drug
abuse and addiction have been linked with HIV/AIDS since
the beginning of the epidemic (Reddy et al., 2012). Substance
abuse is a major barrier in eradication of the HIV outbreak
the reason is that, it serves as a powerful co-factor for
transmission of virus, disease progression, and AIDS related
mortality. Cocaine is one of the commonly abused drugs
among HIV1 patients and it has been suggested to accelerate
AIDS progression. However, the principal mechanism remains
largely unknown, but in recent times it was been shown
that cocaine alter the behavior and mood, causing feelings
of euphoria by stimulating key pleasure centers within the
brain. One of the most damaging effects of cocaine abuse
is that it compromises judgment capacity leading to risky
sexual behavior, thereby increasing chances of contracting HIV
infection. Cocaine is the second most popular abused drug
in United States (Zenón et al., 2014). It is a powerfully
addictive CNS stimulating drug, which increases the level
of neurotransmitter DA in the brain. It has been associated
with known adverse effects on cardiac, gastrointestinal tract,
cerebrovascular, and pulmonary systems. Cocaine abuse increases
the incidence and severity of HIV neuropathology and associated
cognitive deficits by enhancing viral replication. Enhancement
of AIDS pathology includes multiple immunomodulatory effects
of cocaine, its capability to dysregulate neurotoxins such as
quinolinic acid (QUIN) and arachidonic acid (AA) metabolites
and exacerbates neurotoxicity by co-operating with viral toxins
(Yao et al., 2009; Nair and Samikkannu, 2012). Additionally
cocaine is also familiar as an immunosuppressant and is
capable of reducing number and distribution of immune
cells, white blood cells and thymocytes. The battle between
human and the HIV are on, with both of them rapidly
improving their attacking and defense strategies (Saxena et al.,
2002).
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Role of Cocaine in Bypassing Blood Brain
Barrier
Entry of HIV virus in CNS serves as the major factor for the
development of the neuropathological condition and disease
severity. Blood brain barrier (BBB) is the major obstacle for
the entry of pathogen in CNS. Drug abuse such as cocaine
disintegrates the structure and function of BBB and increases
the probability of entry of pathogens into CNS. Cocaine causes
BBB dysfunction through the alterations in expression and
conformation of tight junction proteins such as zona occludin 1
(ZO-1) and junctional adhesion molecules 2 (JAM-2), which
causes glial cell activation. This results in BBB cytoskeleton
remolding through various enzymes eventually leading to
neuroinflammation. Cocaine treatment additionally increases
gene expression of factors, including matrix metallopeptidase-1
(MMP-1), that contributes to basement membrane actin
rearrangement forming stress fiber around cerebral vessels.
Persistent loss or conformational changes in tight junction
proteins and reorganization of basement membrane fibers leave
the brain open to peripheral toxin penetration leading to CNS
disorders of cocaine misuse (Kousik et al., 2012). Apart from
this cocaine has been found to increase infiltration of infected
leukocytes from blood vessels into the brain through direct effect
on human brain microvascular endothelial cells (HBMECs) and
indirectly via release of proinflammatory cytokines such as TNF-
a and IFN-g (Wachtman et al., 2007). Exposure of HBMECs to
cocaine stimulates platelet derived growth factor (PDGF) at both
the transcriptional and translational levels, as binding of cocaine
to its related s 1-R receptor leads to the activation of ERK1/2
and JNK MAP kinases. This in turn triggers the release of
Erg-1 transcription factor that enters the nucleus and stimulates
PDGF-BB expression (Kumar, 2011). PDGF-BB is a known agent
involved in disruption of BBB and is involved in cocaine-mediated
decrease in ZO-1 expression involves PDGF-BB. Along with this
cocaine also increases leukocyte–endothelial adhesion which is
accompanied by elevated levels of pro-inflammatory cytokines
and chemokines. Immunostaining and western blotting disclose
increase in TNF-a, IL-6, IL-8, nuclear factor kappa B (NFkB),
activator protein 1 (AP-1), and CCR2. In vitro BBB model
showed these inflammatory signals are co-related with increased
viral invasion of macrophage-trophic HIV possibly explaining
greater neuropathology detected in patients co-morbid for HIV
infection and cocaine abuse (Gandhi et al., 2010). This provides
a picture of the effects of cocaine on BBB defined by cocaine
induced neuroinflammation. Clinical studies reveal similar BBB
breakdown in the basal ganglia and increased HIV penetration
into the CNS of cocaine-abusing humans (Kousik et al., 2012).
Cocaine and HIV-associated
Neurocognitive Disorder
Neurologic complications may occur up to 40% of AIDS patients
and nearly 25% of HIV infected persons who have not clinically
progressed to AIDS (Carvour et al., 2015). During the later
stages of the disease, HIV-1 infected patients suffer from a wide
range of neurological and neurocognitive disorders collectively
known as HIV-associated neurocognitive disorder (HAND;
Atluri et al., 2014). It is characterized by neuroinflammation,
including astrogliosis, multinucleated giant cells, and neuronal
apoptosis that is linked to progressive virus infection and immune
deterioration (Saiyed et al., 2011). Neuronal apoptosis, a result
of neuronal dysfunction, stands as one of the features of HIV-
associated dementia which is induced by diverse cellular and
viral factors, inclusive of viral proteins Tat and gp120. Drugs of
abuse act synergistically with HIV proteins to potentiate HIV
related neurotoxicity (Yuan et al., 2015) and affect many functions
associated with the synaptic plasticity. Introduction of the anti-
retroviral therapy (ART) has decreased the cases of HAND.
However, drug abuse is playing a crucial role in the prevalence
of HAND in the HIV infected individuals. Cocaine use serves
as a potential factor for the progression to the HAND in the
HIV infected persons. One proposed mechanism is via formation
of platelet monocyte complexes (PMCs). Interaction between
monocytes and activated platelets leads to the formation of PMCs,
and these monocytes has enhanced capability to cross trans-
endothelial barrier and cause neuroinflammation, which possibly
results in HAND (Tiwari et al., 2013). Along with the PMCs
formation, cocaine also induces neuronal apoptosis by triggering
viral products such as Tat and gp120, and potentiates astrocyte
toxicity after activation by HIV gp120 (Yang et al., 2010). gp120
is necessary for the viral infectivity, enhances neurotoxicity via
inducible nitric oxide synthesis, and causes cellular oxidative
stress which increasingly affects the CNS (Figure 2). It also alters
the host glutamate pathway signaling, which interactswith cellular
receptor, directing secretion of cytokines and finally affecting the
neurons (Samikkannu et al., 2011). Cocaine along with gp120 has
been shown to synergistically increase neuronal toxicity. This has
been defined by the increase in the activity of caspase-3, increase
in reactive oxygen species and loss of mitochondrial potential.
Studies have also suggested that cocaine and gp120 alone are
capable of eliciting signaling transduction pathways in neurons,
involving mitochondrial membrane potential loss, oxidative
stress, activation of JNK, p38, and ERK/MAPK pathways, and
results in downstream activation of NF-kB (Yao et al., 2009). In
vitro studies have shown that neuronal toxicity has been found to
be associated with increased cathepsin B secretion in MDM with
HIV infection along with cocaine treatment (Zenón et al., 2014).
Effect of Cocaine and HIV Proteins on
Dopamine Transporter
Dopamine is a neurotransmitter that is produced from amino acid
tyrosine and belongs to the catecholamine family. DA synthesis
occurs in the cytoplasm of the neuron and then it is transported
within the secretary vesicles of the neuron for storage and
subsequent discharge. Once put away at nerve terminals, DA is
prepared to be released into the synaptic cleft and subsequently,
a greater part of it is recaptured by the dopamine transporter
(DAT), which is present in the pre synapticmembrane (Figure 3A,
Giros et al., 1992; Rudnick, 2011). The high concentrations of
DA at synaptic cleft causes apoptosis or inflammation to the
tissue. There are three main pathways controlled by DA, firstly
the pathway of the nigro striatal system, secondly the forebrain
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FIGURE 2 | The sequence of events that leads to progression toward HIV associated Neurocognitive Disorders (HAND) during cocaine abuse,
cocaine + HIV infection and HIV infection alone. Drug abuse (Cocaine) leads to the formation of platelet monocyte complexes (PMCs) which crosses
transendothelial barrier and cause neuroinflammation, which possibly results in HAND. Along with the PMCs formation, cocaine also induces neuronal apoptosis by
triggering viral products such as Tat and gp120, and potentiates astrocyte toxicity after activation by HIV gp120. gp120 is necessary for the viral infectivity, enhances
neurotoxicity via inducible nitric oxide synthesis, and causes cellular oxidative stress which increasingly affects the CNS. It also alters the host glutamate pathway
signaling, which interacts with cellular receptor, directing secretion of cytokines and finally affecting the neurons. Cocaine along with gp120 synergistically increases
neuronal toxicity by the increase in the activity of caspase-3, increase in reactive oxygen species and loss of mitochondrial potential. Cocaine and gp120 are capable
of eliciting signaling transduction pathways in neurons, involving mitochondrial membrane potential loss, oxidative stress, activation of JNK, p38, and ERK/MAPK
pathways, and results in downstream activation of NF-kB that leads to HAND.
that includes cerebral cortex, nucleus accumbens and other limbic
structure and finally tubero-infundibular pathway, in which DA
release occurs directly in the portal system.
Dopamine dysregulation has been associated with HAND, and
evidence has implicated brain regions rich in DA are highly
susceptible to the effects of HIV (Jacobs et al., 2013). The DAT is
critical forDAhomeostasis, which is important for neurocognitive
function and this is the target for HIV viral proteins and cocaine.
Tat acts as an allosteric modulator of DAT, where as cocaine
acts as reuptake inhibitor (Figure 3B). The DAT serves as the
primary mechanism for regulating dopaminergic tone in the
synapse and it is directly affected by HIV-1 infection and cocaine.
This in turn intensifies viral replication and Tat release, resulting
in compromised DA function and the manifestation of HAND
(McIntosh et al., 2015).
Macrophages hold a major part in HIV mediated
neuropathogenesis and may function as viral reservoirs within
the CNS. Macrophages are also found to release inflammatory
mediators and neurotoxic viral and host proteins, causing
chronic neuroinflammation. Thus, HIV infection of infiltrated
macrophages of CNS is critical to HIV-associated neurocognitive
dysfunction and neuroinflammation. Macrophages in the CNS
are exposed to DA, which is increased by illicit drugs such
as cocaine and methamphetamine. Study showed that DA at
concentrations above 10 8 M caused approximately twofold
increase in HIV entry into human primary monocyte-derived
macrophages (Gaskill et al., 2014).
During the synergistic effect of HIV infection and cocaine
abuse, the levels of DA increases in the synaptic cleft. The studies
showed thatDA increasesHIV replication in humanmacrophages
through activation of DA receptor, increasing the total number
of infected cells. The mechanism(s) by which this occurred are
unclear, but one possibility is by increasing HIV entry into
macrophages. HIV entry is complex, and in macrophages, it is
mediated by the interaction of the viral envelope protein gp120
with the surface receptor cluster of differentiation 4 (CD4) and
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FIGURE 3 | Mechanism of Dopamine reuptake by DAT receptor (A) and blocking of the DAT receptor by cocaine and HIV Tat protein (B). (A). Dopamine,
transmits brain signals by flowing from presynaptic neuron into the synaptic cleft and attaching to a receptor (DRD 1,5, and DRD 2,3,4) on postsynaptic neuron. In
general, excess dopamine is recycled into the presynaptic neuron by a dopamine transporter (DAT) on the surface of the presynaptic neuron. The recycled dopamine
is then degraded into homovanillic acid via monoamine oxidase (MOA). (B-a). In this case of cocaine drug abuse, the drug (cocaine) attaches to the DAT and blocks
the normal recycling of dopamine, causing an increase of dopamine levels in the spaces between neurons that lead to inflammation. (B-b). The dopamine recycling is
also inhibited by the Tat protein of HIV by bringing about conformational changes in DAT. The high concentration of dopamine in the synaptic cleft causes
inflammation.
CCR5 on the macrophages (Sundaravaradan et al., 2006) or
through alternative pathways such as the endocytic pathway or
through interaction with the co-receptor CXCR4 or minor co-
receptors including CCR3 (Peters et al., 2004). DA is able to
modulate macrophage functions because macrophage expresses
DA receptors.
Cocaine and Tat Protein Impairs
Neurogenesis
Mounting evidence specifies that along with neuronal loss on
the brains of patients with HIV-associated CNS disease, there is
also evidence of smaller number of neural stem/cells (NPCs) in
the dentate gyrus of the hippocampus. There occurs continuous
generation of new dentate granule from neural progenitor cells,
which gets integrated into the existing hippocampal circuitry in
the adult mammalian brain by a process termed as neurogenesis
(Yao et al., 2012). HIV trans-activating protein Tat, which is
released by infected cells and also taken up by neighboring cells
has been shown to impair neurogenesis (Mishra et al., 1989).
In addition to this, cocaine also diminishes the proliferative rate
of NPCs by negatively affecting the self-renewal capacity of the
hippocampus (Yao et al., 2012). Such defect could explain the
reason for increased prevalence of behavioral deficits detected in
patients with HAND in the post-ART era.
Role of CD4+ T-cell and PBMC in Cocaine
Associated HIV Infection
The entry of HIV into cells requires the interaction of the viral
exterior envelope glycoprotein gp120 with the CD4 receptor,
which is expressed on the surface of the T cells, monocytes,
macrophages and dendritic cells. The interaction of CD4 and
gp120 allows the fusion of viral and host cellular membranes
(Collman et al., 1990; Kwong et al., 1998). The intake of
HIV-1 by antigen presenting cells (APCs) and successive transfer
of virus to CD4+ T cells can bring about significant levels
of virus replication in the T cells (Rinaldo, 2013). Several
studies have shown that cocaine abuse during HIV infection
promotes the viral replication in CD4+ T cells and progression
to AIDS. It was also suggested that CD4+ T-cell counts is
lower in cocaine-abusing HIV patients in comparison to no
abusers patients along with augmented decline in CD4+ T
cell count (Chaisson et al., 1989; Anthony et al., 1991; Cook,
2011; Rafie et al., 2011). The effect of the cocaine abuse in
HIV infected individuals can be preceded by the in vitro study
showing that cocaine along with the HIV virion induces the
apoptosis in the CD4+ T cell (Pandhare et al., 2014). Apoptosis
was merely the result of the increment of the reactive oxygen
species and induction of the mitochondrial depolarization by
cocaine.
Apart from these, it has also been shown that micro RNA
miR125b has a prime role in eliciting anti-HIV role and decreases
HIV replication in CD+4 T cells. 30UTR region of HIV-1 is the
target for miR-125b and inhibit viral protein translation. Cocaine
in such individuals reduces the expression of miR125b and
promotes viral replication (Mantri et al., 2012). Integration is the
important part in the replication of the virus in host cells. Cocaine
in such case has been found to promote HIV-1 integration in host
genome (Addai et al., 2014). Underlying mechanism is revealed
as the consequence of induction of global DNA de-methylation in
CD4+ T cells, which is concurred with the suggestion that DNA
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methylation disfavor integration of HIV-1. Cocaine has been
found to differentially regulate the expression of numerous key
host proteins that perhaps have an influence onHIV-1 replication,
when proteomics analysis was done for cocaine-treated peripheral
blood mononuclear cells (PBMCs) collected from HIV positive
individuals. Cocaine has been shown to boostHIV-1 replication in
immune cells as well as dendritic cells, macrophages and PBMCs
(Reynolds et al., 2009).
Future Perspective
Cocaine is one of the commonly abused drugs among HIV/AIDS
patients and it has been suggested to accelerate AIDS progression.
Cocaine not only increases the migration of peripheral HIV-
infected leukocytes into CNS, but also modulates the disease
status and possibility result in the neuroAIDS. A better
understanding of DA and DAT role may give a clue in
cocaine and AIDS progression. The mechanism of cocaine
drug abuse and neuroAIDS will probably require knowledge
of the interrelationship of the different variables, rather than
concentrating on certain particular zones. Further study is
required to advance the research toward the identification of
new methodologies for the novel drug delivery system that can
pass through the BBB and treat neuroAIDS. Additional research
is needed to build upon from what has already been known,
for this the scientists from neurobiology and infectious diseases
should work collaboratively to conduct the preclinical studies and
every other pathway has to be examined. A co-ordinate effort is
required by researchers, doctors, drug makers, policy makers,
government bodies nationally, and all around to combat the
neuroAIDS. Emphasis should be laid on rehabilitation of cocaine
abusers so that the chances of disease progression can be halted.
Considering the seriousness of the diseases, it’s imperative to be
advised to bring information about HAND into HIV prevention
and awareness programs, particularly to encourage early diagnosis
and treatment.
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